The LifeSci blog reported this morning on some key statistics and trends in Biotech M&A in 2012. Not surprisingly, some data were good, some bad and some ugly (according to LifeSci). Here's the summary:
- Median investor multiples in the US have risen from 1.2x in 2005, to 2.5x in 2011 to a nice 3.5x in 2012. Going my way?
- Unfortunately, this is NOT the case in Europe where the comparable 2012 figure was only 1.3x
- The ugly trend is that the time from founding the company to trade sale is lengthening -- from about 5 years in 2005 to more than 9 years in 2012. Looks similar to trend line for FDA approvals on new drugs. Coincidence?
Posted by Bruce Lehr Jan 30th 2013.